# Artificial Intelligence In Omics Studies Market > Artificial Intelligence In Omics Studies Market Research Report By Type of Omics Studies (Genomics, Transcriptomics, Proteomics, Metabolomics, Epigenomics), By Application (Disease Diagnosis, Drug Discovery, Personalized Medicine, Biomarker Discovery, Toxicology Studies), By AI Technique (Machine Learning, Deep Learning, Natural Language Processing, Computer Vision, Data Mining) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 22.76% - **2024:** $ 6.69 Billion - **2025:** $ 8.21 Billion - **2035:** $ 63.85 Billion - **Key Players:** Illumina (US), Thermo Fisher Scientific (US), Roche (CH), Agilent Technologies (US), Bio-Rad Laboratories (US), Qiagen (DE), PerkinElmer (US), Bristol-Myers Squibb (US), Ginkgo Bioworks (US) **Report ID:** MRFR/HCIT/20632-HCR · **Pages:** 128 · **Author:** Satyendra Maurya & Rahul Gotadki · **Last Updated:** May 15, 2026 **URL:** https://www.marketresearchfuture.com/reports/artificial-intelligence-in-omics-studies-market-22232 --- ## Market Summary ## **Global Artificial Intelligence in Omics Studies Market Overview** As per MRFR analysis, the Ai In Omics Studies Market Size was estimated at 6.69 (USD Billion) in 2024. The Ai In Omics Studies Market Industry is expected to grow from 8.21 (USD Billion) in 2025 to 52.01 (USD Billion) till 2034, at a CAGR (growth rate) is expected to be around 22.76% during the forecast period (2025 - 2034). ### **Key Artificial Intelligence in Omics Studies Market Trends Highlighted** Omics research is currently undergoing a revolution due to Artificial intelligence, which is providing transformative capabilities in data analytics as well as biomarker discovery and personalized medicine. According to the forecast provided by the Market Research Future (MRFR), the AI in Omics Studies Market is expected to grow at a CAGR of 22.76% over the period of 2023-2032, with an estimated value of USD 34.5 billion by 2032. The increase in the totals and intricacy of Omics data merged with precision medicine demand has facilitated the integration of AI into Omics studies. There are several main factors that enable the market to include such as AI’s capacity to accelerate data processes and analysis, improve forecast modeling, and create individualized healthcare plans. Some trends in this space indicate the emergence of deep learning, machine learning, and cloud computing. These techniques have made it possible for AI algorithms to handle huge quantities of Omics data by providing capabilities for efficiently and accurately handling large volumes of Omics data using AI algorithms. In addition, interpretable AI has been stressed to foster AI models’ transparency and accountability towards gaining trust within the medical sector. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **Artificial Intelligence in Omics Studies Market Drivers** ### **Key Market Drivers for the Global Artificial Intelligence in Omics** #### **Increasing Adoption of AI in Healthcare and Life Sciences Research** Healthcare and life sciences are changing fast due to artificial intelligence (AI). At present, AI-supported instruments are being used to make predictions based on a volume of data and identify patterns that can enhance patient care as well as speed up drug discovery. This is expected to be the case in the future thus driving Artificial Intelligence in Omics Studies Market Industry growth. ### **Rising Need for Customized Healthcare** In other words, personalized medicine requires health systems to take into account individual differences based on genetic variation, environmental factors, and lifestyle. Today, big data is being analyzed by artificial intelligence (AI) for the identification of personalized patterns. Accordingly, these data could be used in the creation of custom treatments and interventions that have a higher chance of success. ### **Government Initiatives and Funding** Governments all over the world have started acknowledging the impact of AI on healthcare delivery systems as well as life science. They have increased funding for research and development projects in this area. The favorable environment being created will continue boosting Artificial Intelligence in Omics Studies Market Industry growth. ## **Artificial Intelligence in Omics Studies Market Segment Insights** ### **Artificial Intelligence in Omics Studies Type of Omics Studies Insights** The Type of Omics Studies segment plays a crucial role in shaping the Artificial Intelligence in Omics Studies Market. This market is divided into five major sub-segments: genomics, transcriptomics, proteomics, metabolomics and epigenomics. That year, genomics as a whole-genome information research method accounted for the largest part of the market at USD 1.85 billion due to the ascendency of [Next Generation Sequencing](../../../reports/next-generation-sequencing-market-6354) (NGS) technologies and increasing numbers of genome sequencing projects; in addition, further growth has been achieved through increased need for RNA sequencing services that support biomarker discovery and drug development activities. Transcriptomics is forecasted to grow at a CAGR of 20.5% by 2032, reaching USD 8.2 billion towards the end of the forecast period. Proteomics, on the other hand, will register a CAGR of 21.5% during this period, with its value hitting USD 7.5 billion by 2032, and it’s expected that this increase will be driven by increased use of proteomic techniques in disease diagnosis, identification of biomarkers and drug discovery projects’ purposes. Metabolomics segment, which analyzes small molecules called metabolites, is another fast-growing one projected to reach $4.2bn by 2032, showing a CAGR of 23.5%. The reason behind Metabolonics’ growth is its use in metabolic pathway analysis, marker identification and individualized therapy; nevertheless, Epigenetics or chemical modification study on specific genes on DNA stands a smaller field with much hope ahead, too. Epigenetic treatment potentiality, including recognition among various disease initiation mechanisms, accounts for approximately estimated growth rate from 2015 up to 2032, amounting to $USD2.8bn at about 25.5%. To sum up, the Type of Omics Studies gives profitable opportunities for companies operating within the Artificial Intelligence in Omics Studies Market. With more applications being discovered every day for AI in omic studies, there is little doubt that adoption rates will continue rising exponentially. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ### **Artificial Intelligence in Omics Studies Application Insights** Omics Studies, Disease Diagnosis, Drug Discovery, Personalized Medicine, Biomarker Discovery and Toxicology Studies are the five categories to which the Artificial Intelligence in Omics Studies Market Application is classified. In 2023, the highest demand for early and accurate disease diagnosis will mean that Disease Diagnosis takes the largest market share. On the other hand, personalized therapies have led to an upsurge in the number of drugs being produced; hence drug discovery sector will experience the highest growth rate among others. However, it is worth noting how important personalized medicine can be as treatment plans may be developed based on individual genetic profiles. The biomarkers discovery is a critical step towards finding disease-specific markers used in diagnosis and prognosis. Conversely, AI aids toxicological studies by evaluating chemicals for toxicity and safety concerns. ### **Artificial Intelligence in Omics Studies AI Technique Insights** The Global Market For Artificial Intelligence In Omics Studies Is Categorized Based On AI Techniques Into Machine Learning, Deep Learning, Natural Language Processing, Computer Vision And Data Mining. Out of these, the Machine Learning segment is expected to have the largest market share at about 40% by 2024 and reach a valuation of approximately USD 13.6 billion by 2032, growing at a CAGR of 21.5% during the forecast period; it owes its success to growing adoption of machine learning algorithms in omics studies for data analysis and pattern recognition. Another notable segment is Natural Language Processing with an anticipated growth rate of 24.2% over the forecast period due to its ability to handle large volumes of unstructured text data such as scientific literature and patient records. The Computer Vision sector will also record significant progress as image analysis techniques are increasingly used in omics studies for disease diagnosis and drug discovery. ### **Artificial Intelligence in Omics Studies Regional Insights** The North American area is one of the prime contributors, and the market is expected to reach USD 20.4 Billion by 2032, growing at a CAGR of 22.76% from 2024 to 2032. This can be attributed to reasons like increased investment in healthcare IT, rise in demand for personalized medicine and AI technologies used for data analysis and interpretation, among others. The European market will grow significantly due to its well-established healthcare system and high research spending. On the other hand, South America and MEA would grow at a steady pace because there are more medical facilities available and more skilled professionals on board. APAC has recently come up rapidly due to the faster-expanding healthcare sector and increasing governmental emphasis on AI technology. The Omics Studies Artificial Intelligence (AI) market is expected to achieve significant growth in the years ahead with the North American region seen as a key part of this. The regional market size is projected to reach USD 20.4 billion by 2032, growing at a CAGR of 22.76% from 2024 to 2032, thus boosting demand for AI in genomics and proteomics applications. This development comes as a result of several drivers, including enhanced healthcare IT spending, an increasing need for personalized medicine, and the application of AI technologies in data analysis and interpretation. Europe is also likely to be instrumental in the expansion due to its advanced health infrastructure and heavy R budgets. There are immense growth opportunities present within APAC because of its speedy development medical care industry together with the upsurge government’s involvement in AI. South America and MEA are anticipated to witness steady growth, driven by expanding healthcare facilities and the availability of skilled professionals as well. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **Artificial Intelligence in Omics Studies Market Key Players And Competitive Insights** Artificial Intelligence in Omics Studies Market has its major players in the industry making continuous investments in R&D to enhance their offerings and gain a competitive advantage. Leading the market for Artificial Intelligence in Omics Studies are companies such as IBM, Google, Microsoft, Amazon and NVIDIA, who look forward to formulating new approaches through which researchers would analyze large volumes of data that is complex. This is possible by building partnerships with other organizations or even going into new markets. As a case in point, IBM has taken up a partnership with the University of Oxford to establish AI that is brand new, and that can be used to analyze genetic information and thus help scientists identify any genetic abnormalities that may lead to diseases. Moreover, the growth of Artificial Intelligence (AI) in the Omics Studies Market is prompted further by the escalating adoption of artificial intelligence (AI) and machine learning technologies (ML) in the healthcare sector. The use of AI and ML could aid in the automation of processes leading to better precision as well as providing insights to enable better decisions by researchers. For instance, AI can detect patterns within genetic data that might be associated with diseases. From this point forward, it can be used to construct diagnostic strategies for illness as well as prescription strategies. The availability of large and intricate datasets has also contributed to market expansion. The emergence of next-generation sequencing (NGS) technologies has made it possible to produce enormous quantities of information for studying the human genome. Therefore, such data are then scrutinized by AI or ML, which can detect patterns that signify diseases. Another key player in Artificial Intelligence in Omics Studies Market is Illumina Inc., which is one of the leading providers of NGS instruments as well as reagents based kits for DNA sequencing, etc. The company also develops software employing artificial intelligence algorithms specifically designed for genomics interpretation.”Google partnership:” Additionally, Microsoft has joined hands with Illumina at developing novel artificial intelligence solutions in the health sector”. This company also invests largely in research and development so that it may improve on its capabilities by using AI like developing some new algorithms able to detect some specific genes associated with illnesses. In addition, Illumina is developing new AI tools for drug design and validation. ### **Key Companies in the Artificial Intelligence In Omics Studies Market Include:** - [Pacific Biosciences](https://www.pacb.com/press_releases/pacbio-and-google-collaborate-to-use-machine-learning-to-optimize-long-read-sequencing-data-analysis/) of California, Inc. - Myriad Genetics, Inc. - BD (Becton, Dickinson and Company) - BioRad Laboratories, Inc. - Oxford Nanopore Technologies, PLC - PerkinElmer, Inc. - Agilent Technologies - Sequenom, Inc. - QIAGEN - Illumina, Inc. - Trimble Inc. - Abbott Laboratories - [Thermo Fisher Scientific](https://www.thermofisher.com/blog/behindthebench/bringing-artificial-intelligence-and-automation-to-genetic-analysis/) - HoffmannLa Roche Ltd. - Novogene Co., Ltd. ## **Artificial Intelligence in Omics Studies Market Industry Developments** During the next few years, it is expected to witness a significant increase in the Omics Studies Artificial Intelligence (AI) market owing to improvements in AI algorithms, increased use of omics technologies and the growing demand for [personalized medicine](../../../reports/us-personalized-medicine-market-11715). IBM, Thermo Fisher Scientific, Illumina, QIAGEN and Agilent Technologies are some of the players operating in this market.  The latest developments in this market include but are not limited to new AI-based omics analysis platforms such as IBM’s Watson for Genomics or Thermo Fisher’s Ion Torrent Genexus System, which enable researchers to perform much easier and accurate analyses on huge datasets of omics, hence improving biomarker discovery and drug development.  Moreover, market growth is also fueled by the increasing adoption of cloud-based omics analysis solutions, which provide researchers with scalable and cost-effective computational resources through cloud computing. ## **Artificial Intelligence in Omics Studies Market Segmentation** ### **Artificial Intelligence In Omics Studies Market Type Outlook** - Genomics - Transcriptomics - Proteomics - Metabolomics - Epigenomics ### **Artificial Intelligence In Omics Studies Application Outlook** - Clinical Diagnostics - Drug Discovery & Development ### **Artificial Intelligence In Omics Studies Technology Outlook** - Machine Learning - Deep Learning - Others ### **Artificial Intelligence in Omics Studies Offering Outlook** - Software - Services ### **Artificial Intelligence In Omics Studies Regional Outlook** - North America - Europe - South America - Asia Pacific - Middle East and Africa ## Market Drivers ### Advancements in Data Analytics The rapid advancements in data analytics technologies significantly influence the Artificial Intelligence in Omics Studies Market. With the exponential growth of biological data generated from genomics, proteomics, and metabolomics, traditional analytical methods often fall short. AI algorithms, particularly machine learning and deep learning, offer sophisticated tools for processing and interpreting complex datasets. This capability is crucial, as it is estimated that the volume of omics data will increase by over 30% annually. As researchers and clinicians seek to derive actionable insights from this data, the reliance on AI-driven analytics is expected to surge, thereby propelling the market forward. ### Rising Demand for Precision Medicine The increasing emphasis on precision medicine is a pivotal driver for the Artificial Intelligence in Omics Studies Market. As healthcare shifts towards personalized treatment plans, the need for advanced analytical tools becomes paramount. AI technologies facilitate the analysis of vast omics data, enabling healthcare professionals to tailor therapies based on individual genetic profiles. This trend is underscored by a projected growth rate of approximately 12% in the precision medicine sector, which directly correlates with the demand for AI-driven omics solutions. Consequently, the integration of AI in omics studies is likely to enhance the efficacy of treatments, thereby improving patient outcomes and driving market expansion. ### Increased Investment in Biotechnology The surge in investment within the biotechnology sector serves as a significant catalyst for the Artificial Intelligence in Omics Studies Market. Venture capital funding and government grants are increasingly directed towards innovative biotechnological research, particularly in omics studies. This influx of capital is likely to foster the development of AI applications that enhance data interpretation and accelerate research timelines. Reports indicate that biotechnology investments have reached unprecedented levels, with a notable increase of 25% in funding over the past year. Such financial backing not only supports the integration of AI technologies but also encourages collaboration among research institutions, further driving market growth. ### Growing Need for Efficient Drug Discovery The quest for more efficient drug discovery processes is a critical driver for the Artificial Intelligence in Omics Studies Market. Traditional drug development is often lengthy and costly, with high failure rates. AI technologies streamline this process by enabling researchers to analyze omics data more effectively, identifying potential drug candidates and biomarkers with greater accuracy. The pharmaceutical industry is increasingly adopting AI-driven approaches, with estimates suggesting that AI could reduce drug discovery timelines by up to 50%. This shift not only enhances the likelihood of successful outcomes but also positions AI as an indispensable tool in modern drug development, thereby expanding its market presence. ### Emergence of Collaborative Research Platforms The emergence of collaborative research platforms is reshaping the landscape of the Artificial Intelligence in Omics Studies Market. These platforms facilitate the sharing of omics data and AI tools among researchers, fostering innovation and accelerating discoveries. By breaking down silos, collaborative initiatives enhance the collective understanding of complex biological systems. The trend towards open science and data sharing is gaining momentum, with numerous institutions and organizations committing to collaborative frameworks. This shift is likely to enhance the application of AI in omics studies, as shared resources and expertise can lead to more robust findings and advancements in the field. ## Future Outlook The Artificial Intelligence in Omics Studies Market is projected to grow at a 22.76% CAGR from 2025 to 2035, driven by advancements in data analytics, personalized medicine, and increased research funding. **New opportunities:** - Development of AI-driven genomic data analysis platforms - Integration of machine learning in drug discovery processes - Creation of personalized health management solutions using omics data By 2035, the market is expected to be robust, driven by innovative applications and strategic partnerships. ## Segment Insights ### By Type: Genomics (Largest) vs. Proteomics (Fastest-Growing) The 'Artificial Intelligence in Omics Studies Market' is characterized by distinct segments, with Genomics leading the market share due to its significant application in precision medicine and genetic research. Genomics utilizes advanced algorithms to analyze sequence data, making it an essential component in studying genetic variations. On the other hand, Proteomics is gaining traction, driven by the need to understand protein interactions and functions, placing it as the fastest-growing segment in recent times. Genomics (Dominant) vs. Proteomics (Emerging) Genomics stands out as a dominant force in the Artificial Intelligence in Omics Studies Market, where its applications in human health, agriculture, and pharmaceuticals are extensive. The segment benefits from a wealth of genomic data and robust computational tools that facilitate intricate analyses of genetic information. Conversely, Proteomics, while currently emerging, is swiftly making strides due to its role in biomarker discovery and disease diagnostics. The integration of AI enhances the ability to analyze protein structures and functions, which is crucial as the focus shifts towards personalized medicine, thereby fostering its growth. ### By Application: Clinical Diagnostics (Largest) vs. Drug Discovery & Development (Fastest-Growing) The application segment of the Artificial Intelligence in Omics Studies Market is predominantly led by Clinical Diagnostics, which plays a crucial role in leveraging vast omics data to enhance disease diagnosis and patient management. This sub-segment holds significant market share due to its physician-friendly AI tools and advanced algorithms that cater to healthcare professionals, resulting in quicker and more accurate diagnoses. On the other hand, the Drug Discovery & Development segment is emerging rapidly, driven by technological advancements in AI that enhance the identification of new drug candidates. This segment benefits from the ability to process complex genomic data and identify potential therapeutic targets, thus accelerating the time taken for drug development and potentially lowering costs associated with traditional methods. Application: Clinical Diagnostics (Dominant) vs. Drug Discovery & Development (Emerging) Clinical Diagnostics represents the dominant application in the Artificial Intelligence in Omics Studies Market, characterized by its established role in improving diagnostic accuracy and personalized medicine approaches. This segment's growing use of AI technologies to analyze genomic and proteomic data supports healthcare professionals in making informed decisions. In contrast, Drug Discovery & Development, while currently emerging, is rapidly gaining traction due to its innovative applications of AI to streamline the drug development process. This sub-segment utilizes AI to analyze large biological datasets, facilitating quicker identification of viable drug candidates and optimizing existing therapies, thus promising breakthroughs in pharmaceuticals. ### By Technology: Machine Learning (Largest) vs. Deep Learning (Fastest-Growing) The Artificial Intelligence in Omics Studies Market exhibits a diverse technological landscape, with Machine Learning commanding the largest share. This segment leverages statistical methods and algorithms to analyze vast datasets, making it a cornerstone in the realm of omics research. Conversely, Deep Learning is emerging as a formidable contender, harnessing neural networks to simulate human cognitive processes and offering unprecedented accuracy in data interpretation. As organizations seek to unlock complex biological insights, the preference towards Machine Learning remains strong, yet Deep Learning's rapid advancement is reshaping the market dynamics. Technology: Machine Learning (Dominant) vs. Deep Learning (Emerging) Machine Learning continues to dominate the Artificial Intelligence in Omics Studies Market, offering robust capabilities for predictive analytics and pattern recognition. Its established algorithms drive significant efficiencies in genomic sequencing and biomarker discovery, making it a preferred choice for many research institutions. On the other hand, Deep Learning is rapidly establishing itself as an emerging force. By providing enhanced analytical depth and the ability to work with unstructured data, it plays a pivotal role in advancing personalized medicine and healthcare solutions. As both technologies evolve, their interplay could potentially redefine research approaches and therapeutic strategies. ### By Offering: Software (Largest) vs. Services (Fastest-Growing) In the Artificial Intelligence in Omics Studies Market, the 'Offering' segment sees significant market share distribution between Software and Services. Software solutions dominate the landscape, driven by their advanced capabilities in data analysis, predictive modeling, and integration of AI technologies into omics research. This segment has established a solid user base among researchers and institutions that rely on sophisticated software tools to enhance their analytical capabilities in genomics, proteomics, and metabolomics. On the other hand, the Services segment, which encompasses consulting, implementation, and support services, is on a rapid growth trajectory, appealing to organizations seeking customized solutions and expert guidance alongside their software purchases. Offering: Software (Dominant) vs. Services (Emerging) The Software segment in the Artificial Intelligence in Omics Studies Market stands as the dominant force, characterized by its capacity to provide robust and scalable solutions that cater to a variety of omics applications. These software tools are designed to process large datasets efficiently, facilitating advanced genomic, proteomic, and metabolomic analysis. They enable researchers to uncover new insights and accelerate discovery processes. Conversely, the Services segment represents an emerging trend, addressing the need for tailored assistance in leveraging AI technologies. As institutions strive to optimize their research methodologies, services such as training, consulting, and integration are becoming increasingly vital, illustrating an essential support framework for effective software utilization. ## Regional Market Share Analysis ### North America : Innovation and Investment Hub North America is the largest market for Artificial Intelligence in Omics Studies, holding approximately 45% of the global market share. The region benefits from significant investments in biotechnology and healthcare, driven by advancements in AI technologies and increasing demand for personalized medicine. Regulatory support from agencies like the FDA further catalyzes growth, ensuring compliance and safety in AI applications. The United States is the dominant player, with key companies such as Illumina, Thermo Fisher Scientific, and Ginkgo Bioworks leading the charge. Canada also shows promise, with growing investments in AI research and development. The competitive landscape is characterized by a mix of established firms and innovative startups, all vying for a share of this rapidly evolving market. ### Europe : Regulatory Framework and Growth Europe is the second-largest market for Artificial Intelligence in Omics Studies, accounting for around 30% of the global market share. The region's growth is propelled by stringent regulations that promote data privacy and ethical AI use, alongside increasing public and private investments in genomics and biotechnology. The European Union's initiatives to foster innovation in healthcare further enhance market dynamics, creating a conducive environment for AI applications in omics. Leading countries include Germany, the UK, and France, where companies like Roche and Qiagen are making significant strides. The competitive landscape is marked by collaborations between tech firms and research institutions, driving innovation. The presence of regulatory bodies ensures that AI technologies are developed responsibly, aligning with public health goals. "The European Commission is committed to fostering a digital transformation that benefits all citizens," European Commission. ### Asia-Pacific : Rapid Growth and Adoption Asia-Pacific is witnessing rapid growth in the Artificial Intelligence in Omics Studies market, holding approximately 20% of the global market share. The region's expansion is driven by increasing investments in healthcare infrastructure, a growing population, and rising demand for advanced diagnostic tools. Countries like China and India are at the forefront, supported by government initiatives aimed at enhancing healthcare through technology and innovation. China is emerging as a leader in AI research and development, with significant contributions from local companies and universities. India is also making strides, focusing on personalized medicine and genomics. The competitive landscape is characterized by a mix of local startups and multinational corporations, all aiming to leverage AI for better healthcare outcomes. The region's diverse market presents both opportunities and challenges for stakeholders. ### Middle East and Africa : Emerging Market Potential The Middle East and Africa region is an emerging market for Artificial Intelligence in Omics Studies, currently holding about 5% of the global market share. Growth is driven by increasing healthcare investments, a rising prevalence of chronic diseases, and a growing interest in personalized medicine. Governments are beginning to recognize the potential of AI in healthcare, leading to supportive policies and funding initiatives aimed at enhancing research and development in this field. Countries like South Africa and the UAE are leading the charge, with initiatives to integrate AI into healthcare systems. The competitive landscape is still developing, with a mix of local and international players entering the market. As awareness of AI's benefits grows, the region is poised for significant advancements in omics studies, making it an attractive area for investment and innovation. ## Competitive Benchmarking Artificial Intelligence in Omics Studies Market has its major players in the industry making continuous investments in R&D to enhance their offerings and gain a competitive advantage. Leading the market for Artificial Intelligence in Omics Studies are companies such as IBM, Google, Microsoft, Amazon and NVIDIA, who look forward to formulating new approaches through which researchers would analyze large volumes of data that is complex. This is possible by building partnerships with other organizations or even going into new markets. As a case in point, IBM has taken up a partnership with the University of Oxford to establish AI that is brand new, and that can be used to analyze genetic information and thus help scientists identify any genetic abnormalities that may lead to diseases. Moreover, the growth of Artificial Intelligence (AI) in the Omics Studies Market is prompted further by the escalating adoption of artificial intelligence (AI) and machine learning technologies (ML) in the healthcare sector. The use of AI and ML could aid in the automation of processes leading to better precision as well as providing insights to enable better decisions by researchers. For instance, AI can detect patterns within genetic data that might be associated with diseases. From this point forward, it can be used to construct diagnostic strategies for illness as well as prescription strategies. The availability of large and intricate datasets has also contributed to market expansion. The emergence of next-generation sequencing (NGS) technologies has made it possible to produce enormous quantities of information for studying the human genome. Therefore, such data are then scrutinized by AI or ML, which can detect patterns that signify diseases. Another key player in Artificial Intelligence in Omics Studies Market is Illumina Inc., which is one of the leading providers of NGS instruments as well as reagents based kits for DNA sequencing, etc. The company also develops software employing artificial intelligence algorithms specifically designed for genomics interpretation.”Google partnership:” Additionally, Microsoft has joined hands with Illumina at developing novel artificial intelligence solutions in the health sector”. This company also invests largely in research and development so that it may improve on its capabilities by using AI like developing some new algorithms able to detect some specific genes associated with illnesses. In addition, Illumina is developing new AI tools for drug design and validation. ## Recent News & Developments During the next few years, it is expected to witness a significant increase in the Omics Studies Artificial Intelligence (AI) market owing to improvements in AI algorithms, increased use of omics technologies and the growing demand for [personalized medicine](../../../reports/us-personalized-medicine-market-11715). IBM, Thermo Fisher Scientific, Illumina, QIAGEN and Agilent Technologies are some of the players operating in this market.  The latest developments in this market include but are not limited to new AI-based omics analysis platforms such as IBM’s Watson for Genomics or Thermo Fisher’s Ion Torrent Genexus System, which enable researchers to perform much easier and accurate analyses on huge datasets of omics, hence improving biomarker discovery and drug development.  Moreover, market growth is also fueled by the increasing adoption of cloud-based omics analysis solutions, which provide researchers with scalable and cost-effective computational resources through cloud computing. ## Report Scope | MARKET SIZE 2024 | 6.691(USD Billion) | | --- | --- | | MARKET SIZE 2025 | 8.213(USD Billion) | | MARKET SIZE 2035 | 63.85(USD Billion) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 22.76% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Billion | | Key Companies Profiled | Illumina (US), Thermo Fisher Scientific (US), Roche (CH), Agilent Technologies (US), Bio-Rad Laboratories (US), Qiagen (DE), PerkinElmer (US), Bristol-Myers Squibb (US), Ginkgo Bioworks (US) | | Segments Covered | Type of Omics Studies, Application, AI Technique, Regional | | Key Market Opportunities | Integration of advanced machine learning algorithms enhances precision in genomic data analysis within the Artificial Intelligence in Omics Studies Market. | | Key Market Dynamics | Rising integration of artificial intelligence enhances data analysis capabilities in omics studies, driving innovation and efficiency. | | Countries Covered | North America, Europe, APAC, South America, MEA | ## Frequently Asked Questions **Q: What is the projected market valuation of Artificial Intelligence in Omics Studies by 2035?** A: The market is projected to reach approximately 63.85 USD Billion by 2035. **Q: What was the market valuation of Artificial Intelligence in Omics Studies in 2024?** A: The market valuation was 6.691 USD Billion in 2024. **Q: What is the expected CAGR for the Artificial Intelligence in Omics Studies Market from 2025 to 2035?** A: The expected CAGR during the forecast period 2025 - 2035 is 22.76%. **Q: Which segment of the Artificial Intelligence in Omics Studies Market had the highest valuation in 2024?** A: The Epigenomics segment had the highest valuation at 2.0 USD Billion in 2024. **Q: What are the key applications driving the Artificial Intelligence in Omics Studies Market?** A: Key applications include Clinical Diagnostics and Drug Discovery & Development, with valuations of 2.5 and 4.191 USD Billion in 2024, respectively. **Q: Which technology segment is expected to lead the market in the coming years?** A: Machine Learning is expected to lead, with a valuation of 2.5 USD Billion in 2024. **Q: Who are the leading players in the Artificial Intelligence in Omics Studies Market?** A: Key players include Illumina, Thermo Fisher Scientific, Roche, and Agilent Technologies. **Q: What is the projected valuation for the Genomics segment by 2035?** A: The Genomics segment is projected to reach approximately 15.0 USD Billion by 2035. **Q: How does the valuation of Drug Discovery & Development compare to Clinical Diagnostics in 2024?** A: In 2024, Drug Discovery & Development was valued at 4.191 USD Billion, significantly higher than Clinical Diagnostics at 2.5 USD Billion. **Q: What is the expected growth trajectory for the Artificial Intelligence in Omics Studies Market?** A: The market is expected to experience substantial growth, reaching 63.85 USD Billion by 2035. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/artificial-intelligence-in-omics-studies-market-22232*